Spartacus-Biomed

 Posters Sessions:

Saturday June 25th, 2016

 17:20 - 18: 20        

Moderated Poster session 1 (Dr Philippe Rouet and Dr. Romain Harmancey)

Moderated Poster session 2 (Prof. W. Frank Peacock and Pof. Salatore Di Somma)

 Sunday June 26th, 2016

9:00-10:20 Oral Poster Session / Fellow on stage

 Chairmans (Dr Romain Harmancey and Prof. Alan Maisel).

  11:20 - 12: 00     

 Moderated Poster session  (Prof. W. Frank Peacock and Philippe Rouet)
       

Workshops:

 Saturday June 25th, 2016

13:00-14:00

Discussion with Dr. Aba Tomjanonovich (MDE)

MDE Heidelberg supply devices for professional pharmacological and physiological measurements. The unique filtering and professional mechanical solutions are the guaranties to have the less noise and the most precise data.

 16:00-16:40

 Discussion with Madame Nathalie MARNIER (ThermoFisher Scientific)

Spartacus-Biomed a R&D Company

The world global market for in vitro diagnostic tests for cardiac biomarkers was estimated at $3.1 billion in 2012 and nearly $4 billion in 2013. This market is predicted to reach $7.5 billion by 2018, at a compound annual growth rate (CAGR) of 12 % over the next five-year period  (Cardiac Biomarkers: Technologies and Global Markets; Report Code: BIO128A).

Spartacus-Biomed business model is focused on biomarkers which are estimated to peak annual turnovers of up to 800 M€ in Europe. Indeed, heart failure (HF) related biomarkers are being increasingly used to aid for diagnosis, to a much lesser extend for prognosis and to identify sub-populations with differing benefit-risk ratios.   

Spartacus-Biomed  will provide novel Biomarkers that will equip  physicians with tools to improve the early diagnosis of ischemia, to identify patients at risk of developing HF, and to characterize patient subsets with a greater likelihood of response to HF preventive therapies.

This project is funded by Occitanie district.

© 2020.Spartacus-Biomed